Company Overview of PsiOxus Therapeutics, Ltd.
PsiOxus Therapeutics, Ltd., a biotechnology company, develops novel therapeutics that address cancer and other clinically unmet diseases. The company provides MT-102, a dual action anabolic catabolic transforming agent for the treatment of cancer cachexia and sarcopenia; and ColoAd1, a chimeric oncolytic virus for the systemic treatment of metastatic cancer. It also offers PolySTAR, a research phase vaccine platform that combines recombinant viral vectors with polymers to shield them from the immune system; and PolyMAP, a research phase adjuvant and immunotherapeutic platform that combines polymers with synthetic adjuvants for immunogenicity. PsiOxus Therapeutics, Ltd. was formerly known as ...
154B Milton Park
Abingdon, OX14 4SD
Founded in 2006
Key Executives for PsiOxus Therapeutics, Ltd.
Chief Executive Officer and Director
Founder and Member of Scientific Advisory Board
Finance Director, Company Secretary and Director
Compensation as of Fiscal Year 2015.
PsiOxus Therapeutics, Ltd. Key Developments
PsiOxus Therapeutics, Ltd. Presents at BioEquity Europe 2015, May-19-2015 04:20 PM
May 8 15
PsiOxus Therapeutics, Ltd. Presents at BioEquity Europe 2015, May-19-2015 04:20 PM. Venue: InterContinental Vienna, Vienna, Austria.
PsiOxus Therapeutics Expands Clinical Studies for Immuno-Oncolytic Treatment Following Positive Response to Intravenous Delivery
Apr 16 15
PsiOxus Therapeutics Ltd. (PsiOxus) has expanded two of its on-going phase I studies using its anti-cancer treatment candidate, enadenotucirev (EnAd), an oncolytic Ad11/Ad3 chimeric group B adenovirus. The expanded studies, introduce a number of additional cancer types into the programme, as a result of phase I data demonstrating the successful tumour delivery of EnAd through intravenous administration. The treatment was generally well tolerated with repeated dosing. PsiOxus has already enrolled its first patients in each indication of the expanded studies. The initial study, a phase I mechanism of action (MoA) study of intra-tumoural and intravenous administration of EnAd in colon cancer patients, has been expanded to include intravenous delivery to three additional tumour types, non-small cell lung, urothelial bladder and renal cell cancer. Initial results of the MoA study in colon cancer found that intravenous delivery was as effective as intra-tumoural delivery. Additionally, virus replication was reported in the tumour tissue but not the surrounding normal cells, while CD8+ T-cells were shown to have successfully infiltrated the tumour, which is not normally seen in most colon cancers. The EVOLVE (EValuating OncoLytic Vaccine Efficacy) trial has expanded to include repeat intravenous dosing of EnAd in metastatic urothelial bladder cancer. EVOLVE is a first in human phase I/II study to determine the dose, safety, tolerability and potential efficacy of EnAd when delivered intravenously to patients with epithelial cancers. It is the first clinical study to report that live replicating oncolytic virus has been recovered directly from the blood stream of cancer patients. Results of this dose escalation study identified a phase II dose for single and repeat dosing of EnAd via intravenous administration. This feature of EnAd distinguishes it from most other oncolytic viruses, where effective delivery to tumours via intravenous administration is not seen.
PsiOxus Therapeutics, Ltd. Presents at BIO-Europe Spring 2015, Mar-09-2015
Jan 29 15
PsiOxus Therapeutics, Ltd. Presents at BIO-Europe Spring 2015, Mar-09-2015 . Venue: Paris Expo - Porte de Versailles, Hall 5, Paris, France.
Similar Private Companies By Industry
Recent Private Companies Transactions
May 19, 2015